Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients
Bristol Myers Squibb Co. (NYSE:BMY) shares are down on Thursday as the company releases positive interim results from a Phase 3 trial of izalontamab brengitecan (Iza-bren), in collaboration with SystImmune Inc. This news comes as the broader market …